Half-dose for Halcygen
Tuesday, 07 October, 2008
Halcygen Pharmaceuticals (ASX: HGN) has demonstrated the effectiveness of the company's SUBA-itraconazole antifungal in a recent pharmacokinetic trial.
The trial was the first of three pharmacokinetic studies the company is conducting for the Investigational New Drug [IND] application recently approved by the FDA.
Halcygen was able to prove that SUBA-itraconazole in a 'half-dose' format gives comparable pharmacokinetic levels to a full dose of itraconazole market leader Sporanox.
All three pharmacokinetic trials should be complete by the end of the year.
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
